Literature DB >> 23850914

Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).

Chih M Wong1, Nathaniel M Hawkins, Pardeep S Jhund, Michael R MacDonald, Scott D Solomon, Christopher B Granger, Salim Yusuf, Marc A Pfeffer, Karl Swedberg, Mark C Petrie, John J V McMurray.   

Abstract

OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).
BACKGROUND: Few studies have focused on young and very young adults with HF.
METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.
RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001). They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002). The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization. Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively). Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively). Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).
CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts. Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired. Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACEI; ARB; CI; HF; HF-PEF; HF-REF; HR; HRQL; IDCM; LVEF; MLwHF; Minnesota Living with Heart Failure; NYHA; New York Heart Association; angiotensin receptor blocker; angiotensin-enzyme converting inhibitor; confidence interval; ejection fraction; hazard ratio; health-related quality of life; heart failure; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; idiopathic-dilated cardiomyopathy; left ventricular ejection fraction; outcome; young

Mesh:

Substances:

Year:  2013        PMID: 23850914     DOI: 10.1016/j.jacc.2013.05.072

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

1.  Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis.

Authors:  Carolyn L Lekavich; Debra J Barksdale; Jia-Rong Wu; Virginia Neelon; Jamie Crandell; Eric J Velazquez
Journal:  J Card Fail       Date:  2017-07-14       Impact factor: 5.712

2.  Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients.

Authors:  Michael Zacharias; Samuel Joffe; Elizabeth Konadu; Theo Meyer; Michael Kiernan; Darleen Lessard; Robert J Goldberg
Journal:  Int J Cardiol       Date:  2015-10-22       Impact factor: 4.164

Review 3.  Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.

Authors:  Carolyn L Lekavich; Debra J Barksdale; Virginia Neelon; Jia-Rong Wu
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

4.  Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children.

Authors:  Javier J Lasa; Michael Gaies; Lauren Bush; Wenying Zhang; Mousumi Banerjee; Jeffrey A Alten; Ryan J Butts; Antonio G Cabrera; Paul A Checchia; Justin Elhoff; Angela Lorts; Joseph W Rossano; Kurt Schumacher; Lara S Shekerdemian; Jack F Price
Journal:  Circ Heart Fail       Date:  2020-04-17       Impact factor: 8.790

Review 5.  Assessing quality-of-life outcomes in cardiovascular clinical research.

Authors:  Daniel B Mark
Journal:  Nat Rev Cardiol       Date:  2016-02-18       Impact factor: 32.419

Review 6.  Epidemiology of cardiovascular disease in young individuals.

Authors:  Charlotte Andersson; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2017-10-12       Impact factor: 32.419

7.  National Rate of Tobacco and Substance Use Disorders Among Hospitalized Heart Failure Patients.

Authors:  Sarah C Snow; Gregg C Fonarow; Joseph A Ladapo; Donna L Washington; Katherine J Hoggatt; Boback Ziaeian
Journal:  Am J Med       Date:  2018-12-16       Impact factor: 4.965

8.  Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes: A National Registry Analysis.

Authors:  Hasina Maredia; Mary Grace Bowring; Allan B Massie; Sunjae Bae; Amber Kernodle; Shakirat Oyetunji; Christian Merlo; Robert S D Higgins; Dorry L Segev; Errol L Bush
Journal:  Circ Heart Fail       Date:  2021-02-02       Impact factor: 8.790

9.  Medications Adherence and Associated Factors among Patients with Type 2 Diabetes Mellitus in the Gaza Strip, Palestine.

Authors:  Aymen Elsous; Mahmoud Radwan; Hasnaa Al-Sharif; Ayman Abu Mustafa
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-09       Impact factor: 5.555

Review 10.  Mortality in heart failure patients.

Authors:  Ibadete Bytyçi; Gani Bajraktari
Journal:  Anatol J Cardiol       Date:  2014-08-19       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.